首页>
外国专利>
GFP MUTAGENESIS AMPLIFICATION: USE OF A FLUORESCENCE-ANTIBIOTIC RESISTANCE FUSION DUAL REPORTER CONSTRUCT TO PROVIDE QUANTITATIVE AND HIGHLY SENSITIVE DETECTION OF MUTATIONS
GFP MUTAGENESIS AMPLIFICATION: USE OF A FLUORESCENCE-ANTIBIOTIC RESISTANCE FUSION DUAL REPORTER CONSTRUCT TO PROVIDE QUANTITATIVE AND HIGHLY SENSITIVE DETECTION OF MUTATIONS
展开▼
机译:GFP突变扩增:使用荧光-抗性融合双报告子构建可定量和高度灵敏的突变检测
展开▼
页面导航
摘要
著录项
相似文献
摘要
A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-β-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis. Quantitative (as opposed to binary) detection of mutations allows substantial savings in test sample. This has applications in drug discovery, allowing high-throughput screening for DNA-targeting compounds and early pre-screening of leads for potential carcinogenic activity. The increased sensitivity of this assay also facilitates monitoring complex environmental samples.
展开▼